<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00378560</url>
  </required_header>
  <id_info>
    <org_study_id>V501-027</org_study_id>
    <secondary_id>2006_032</secondary_id>
    <nct_id>NCT00378560</nct_id>
  </id_info>
  <brief_title>V501 Efficacy Study in Women Aged 18 to 26 (V501-027)</brief_title>
  <official_title>V501 Phase II Efficacy Study in Women Aged 18 to 26</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A study to evaluate the efficacy, immunogenicity, safety and tolerability of V501 in adult
      women
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2006</start_date>
  <completion_date type="Actual">September 16, 2009</completion_date>
  <primary_completion_date type="Actual">September 16, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined Incidence of Persistent Human Papillomavirus (HPV) 6, 11, 16 and 18 Infection or HPV 6, 11, 16 and 18 Related-Disease as Determined by Clinical/Pathologic Criteria and Positive Polymerase Chain Reaction (PCR) Assay for Virus Subtype</measure>
    <time_frame>Over 30 months</time_frame>
    <description>Participants with HPV 6, 11, 16 or 18 persistent infection, and genital disease (e.g., cervical, vaginal or vulval intraepithelial neoplasia, or cancer, adenocarcinoma in situ and genital warts) per 100 person-years of follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 6)</measure>
    <time_frame>At one month after completed vaccination series (Month 7)</time_frame>
    <description>Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers (GMTs) by vaccine group.
The limit of detection of the assay was 7 mMU/ml. GMTs and confidence limits below the limit of detection are shown as &quot;7.0&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 11)</measure>
    <time_frame>At one month after completed vaccination series (Month 7)</time_frame>
    <description>Month 7 HPV cLIA Geometric Mean Titers by vaccine group.
The limit of detection of the assay was 8 mMU/ml. GMTs and confidence limits below the limit of detection are shown as &quot;8.0&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 16)</measure>
    <time_frame>At one month after completed vaccination series (Month 7)</time_frame>
    <description>Month 7 HPV cLIA Geometric Mean Titers by vaccine group.
The limit of detection of the assay was 11 mMU/ml. GMTs and confidence limits below the limit of detection are shown as &quot;11.0&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 18)</measure>
    <time_frame>At one month after completed vaccination series (Month 7)</time_frame>
    <description>Month 7 HPV cLIA Geometric Mean Titers by vaccine group.
The limit of detection of the assay was 10 mMU/ml. GMTs and confidence limits below the limit of detection are shown as &quot;10.0&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1021</enrollment>
  <condition>HPV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine</intervention_name>
    <description>V501; Gardasil, 0.5 ml injection in 3 dosing regimen</description>
    <arm_group_label>2</arm_group_label>
    <other_name>V501</other_name>
    <other_name>Gardasil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo 0.5 ml injection in 3 dosing regimen</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female Subject Aged 18 To 26 Years

          -  With 1-4 Lifetime Sexual Partners

        Exclusion Criteria:

          -  Male Subject
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <results_reference>
    <citation>Yoshikawa H, Ebihara K, Tanaka Y, Noda K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci. 2013 Apr;104(4):465-72. doi: 10.1111/cas.12106. Epub 2013 Mar 7.</citation>
    <PMID>23331518</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2006</study_first_submitted>
  <study_first_submitted_qc>September 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2006</study_first_posted>
  <results_first_submitted>April 21, 2010</results_first_submitted>
  <results_first_submitted_qc>May 27, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 29, 2010</results_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted at 14 sites in Japan from 2006 to 2009.</recruitment_details>
      <pre_assignment_details>There were no specific criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>V501</title>
          <description>V501; Gardasil, 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="509"/>
                <participants group_id="P2" count="512"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="509"/>
                <participants group_id="P2" count="512"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="453"/>
                <participants group_id="P2" count="454"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory test values abnormal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>V501</title>
          <description>V501; Gardasil, 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="509"/>
            <count group_id="B2" value="512"/>
            <count group_id="B3" value="1021"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.7" spread="2.1"/>
                    <measurement group_id="B2" value="22.9" spread="2.1"/>
                    <measurement group_id="B3" value="22.8" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="509"/>
                    <measurement group_id="B2" value="512"/>
                    <measurement group_id="B3" value="1021"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.1" spread="8.2"/>
                    <measurement group_id="B2" value="51.7" spread="7.3"/>
                    <measurement group_id="B3" value="51.9" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Combined Incidence of Persistent Human Papillomavirus (HPV) 6, 11, 16 and 18 Infection or HPV 6, 11, 16 and 18 Related-Disease as Determined by Clinical/Pathologic Criteria and Positive Polymerase Chain Reaction (PCR) Assay for Virus Subtype</title>
        <description>Participants with HPV 6, 11, 16 or 18 persistent infection, and genital disease (e.g., cervical, vaginal or vulval intraepithelial neoplasia, or cancer, adenocarcinoma in situ and genital warts) per 100 person-years of follow up.</description>
        <time_frame>Over 30 months</time_frame>
        <population>Includes participants who were not general protocol violators, received all 3 vaccinations, and were seronegative at Day 1 and PCR negative through Month 7 for the relevant HPV type</population>
        <group_list>
          <group group_id="O1">
            <title>V501</title>
            <description>V501; Gardasil, 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Combined Incidence of Persistent Human Papillomavirus (HPV) 6, 11, 16 and 18 Infection or HPV 6, 11, 16 and 18 Related-Disease as Determined by Clinical/Pathologic Criteria and Positive Polymerase Chain Reaction (PCR) Assay for Virus Subtype</title>
          <description>Participants with HPV 6, 11, 16 or 18 persistent infection, and genital disease (e.g., cervical, vaginal or vulval intraepithelial neoplasia, or cancer, adenocarcinoma in situ and genital warts) per 100 person-years of follow up.</description>
          <population>Includes participants who were not general protocol violators, received all 3 vaccinations, and were seronegative at Day 1 and PCR negative through Month 7 for the relevant HPV type</population>
          <units>Incidence per 100 person-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="61.2" upper_limit="97.7"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Percent Relative Risk Reduction</param_type>
            <param_value>87.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>59.2</ci_lower_limit>
            <ci_upper_limit>97.6</ci_upper_limit>
            <estimate_desc>Binomial probability conditional on the fixed number of events.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 6)</title>
        <description>Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers (GMTs) by vaccine group.
The limit of detection of the assay was 7 mMU/ml. GMTs and confidence limits below the limit of detection are shown as &quot;7.0&quot;.</description>
        <time_frame>At one month after completed vaccination series (Month 7)</time_frame>
        <population>Includes participants who were not general protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 for the relevant HPV type, and had a Month 7 serum sample collected within an acceptable time range</population>
        <group_list>
          <group group_id="O1">
            <title>V501</title>
            <description>V501; Gardasil, 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 6)</title>
          <description>Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers (GMTs) by vaccine group.
The limit of detection of the assay was 7 mMU/ml. GMTs and confidence limits below the limit of detection are shown as &quot;7.0&quot;.</description>
          <population>Includes participants who were not general protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 for the relevant HPV type, and had a Month 7 serum sample collected within an acceptable time range</population>
          <units>Geometric Mean Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="390.8" lower_limit="357.7" upper_limit="426.9"/>
                    <measurement group_id="O2" value="7.0" lower_limit="7.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 11)</title>
        <description>Month 7 HPV cLIA Geometric Mean Titers by vaccine group.
The limit of detection of the assay was 8 mMU/ml. GMTs and confidence limits below the limit of detection are shown as &quot;8.0&quot;.</description>
        <time_frame>At one month after completed vaccination series (Month 7)</time_frame>
        <population>Includes participants who were not general protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 for the relevant HPV type, and had a Month 7 serum sample collected within an acceptable time range</population>
        <group_list>
          <group group_id="O1">
            <title>V501</title>
            <description>V501; Gardasil, 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 11)</title>
          <description>Month 7 HPV cLIA Geometric Mean Titers by vaccine group.
The limit of detection of the assay was 8 mMU/ml. GMTs and confidence limits below the limit of detection are shown as &quot;8.0&quot;.</description>
          <population>Includes participants who were not general protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 for the relevant HPV type, and had a Month 7 serum sample collected within an acceptable time range</population>
          <units>Geometric Mean Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="579.8" lower_limit="538.1" upper_limit="624.8"/>
                    <measurement group_id="O2" value="8.0" lower_limit="8.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 16)</title>
        <description>Month 7 HPV cLIA Geometric Mean Titers by vaccine group.
The limit of detection of the assay was 11 mMU/ml. GMTs and confidence limits below the limit of detection are shown as &quot;11.0&quot;.</description>
        <time_frame>At one month after completed vaccination series (Month 7)</time_frame>
        <population>Includes participants who were not general protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 for the relevant HPV type, and had a Month 7 serum sample collected within an acceptable time range</population>
        <group_list>
          <group group_id="O1">
            <title>V501</title>
            <description>V501; Gardasil, 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 16)</title>
          <description>Month 7 HPV cLIA Geometric Mean Titers by vaccine group.
The limit of detection of the assay was 11 mMU/ml. GMTs and confidence limits below the limit of detection are shown as &quot;11.0&quot;.</description>
          <population>Includes participants who were not general protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 for the relevant HPV type, and had a Month 7 serum sample collected within an acceptable time range</population>
          <units>Geometric Mean Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
                <count group_id="O2" value="365"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2396.4" lower_limit="2201.3" upper_limit="2608.8"/>
                    <measurement group_id="O2" value="11.0" lower_limit="11.0" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 18)</title>
        <description>Month 7 HPV cLIA Geometric Mean Titers by vaccine group.
The limit of detection of the assay was 10 mMU/ml. GMTs and confidence limits below the limit of detection are shown as &quot;10.0&quot;.</description>
        <time_frame>At one month after completed vaccination series (Month 7)</time_frame>
        <population>Includes participants who were not general protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 for the relevant HPV type, and had a Month 7 serum sample collected within an acceptable time range</population>
        <group_list>
          <group group_id="O1">
            <title>V501</title>
            <description>V501; Gardasil, 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
          </group>
        </group_list>
        <measure>
          <title>Vaccine Type Serum Antibody Titer at One Month After Completed Vaccination Series (Anti-HPV 18)</title>
          <description>Month 7 HPV cLIA Geometric Mean Titers by vaccine group.
The limit of detection of the assay was 10 mMU/ml. GMTs and confidence limits below the limit of detection are shown as &quot;10.0&quot;.</description>
          <population>Includes participants who were not general protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 for the relevant HPV type, and had a Month 7 serum sample collected within an acceptable time range</population>
          <units>Geometric Mean Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="389"/>
                <count group_id="O2" value="386"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="369.0" lower_limit="335.9" upper_limit="405.4"/>
                    <measurement group_id="O2" value="10.0" lower_limit="10.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse event data were collected over the entire duration of the study. Other non-serious adverse event data were collected from Day 1 to Day 15 following vaccination.</time_frame>
      <desc>The number of subjects at risk included randomized participants who had follow-up after at least one dose of vaccine.
Unlike many countries, in Japan high-grade cervical intraepithelial neoplasias (eg, cervical dysplasia) are often treated in the hospital and are thus categorized as serious adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>V501</title>
          <description>V501; Gardasil, 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo 0.5 mL intramuscular injection, in 3 dosing regimen, given at Day 1, Month 2, and Month 6</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Ovarian abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="480"/>
                <counts group_id="E2" events="46" subjects_affected="46" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Ovarian cystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="435" subjects_at_risk="480"/>
                <counts group_id="E2" subjects_affected="396" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="480"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="480"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="480"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="480"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site anaesthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site discolouration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="206" subjects_affected="147" subjects_at_risk="480"/>
                <counts group_id="E2" events="154" subjects_affected="99" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site movement impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="867" subjects_affected="397" subjects_at_risk="480"/>
                <counts group_id="E2" events="626" subjects_affected="316" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="480"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="188" subjects_affected="123" subjects_at_risk="480"/>
                <counts group_id="E2" events="84" subjects_affected="57" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="480"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Puncture site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="39" subjects_at_risk="480"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Venipuncture site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Laryngopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Lymph gland infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="59" subjects_affected="52" subjects_at_risk="480"/>
                <counts group_id="E2" events="60" subjects_affected="52" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Purulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Vaginal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Injury corneal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="480"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="480"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="74" subjects_affected="62" subjects_at_risk="480"/>
                <counts group_id="E2" events="67" subjects_affected="50" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervix haemorrhage uterine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="480"/>
                <counts group_id="E2" events="34" subjects_affected="28" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Genital pruritus female</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Oropharyngeal swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="480"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Comedone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="480"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
              <event>
                <sub_title>Urticaria generalised</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="468"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

